成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 82009-34-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 82009-34-5
Chemical Structure| 82009-34-5
Structure of 82009-34-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 82009-34-5 ]

Related Doc. of [ 82009-34-5 ]

Alternatived Products of [ 82009-34-5 ]
Product Citations

Product Citations

Martinez-Erro, Samuel ; Navas, Francisco ; Romani-Cubells, Eva , et al. DOI: PubMed ID:

Abstract: Mesoporous silica nanomaterials have emerged as promising vehicles in controlled drug delivery systems due to their ability to selectively transport, protect, and release pharmaceuticals in a controlled and sustained manner. One drawback of these drug delivery systems is their preparation procedure that usually requires several steps including the removal of the structure-directing agent (surfactant) and the later loading of the drug into the porous structure. Herein, we describe the preparation of mesoporous silica nanoparticles, as drug delivery systems from structure-directing agents based on the kidney-protector drug cilastatin in a simple, fast, and one-step process. The concept of drug-structure-directing agent (DSDA) allows the use of lipidic derivatives of cilastatin to direct the successful formation of mesoporous silica nanoparticles (MSNs). The inherent pharmacol. activity of the surfactant DSDA cilastatin-based template permits that the MSNs can be directly employed as drug delivery nanocarriers, without the need of extra steps. MSNs thus synthesized have shown good sphericity and remarkable textural properties. The size of the nanoparticles can be adjusted by simply selecting the stirring speed, time, and aging temperature during the synthesis procedure. Moreover, the release experiments performed on these materials afforded a slow and sustained drug release over several days, which illustrates the MSNs potential utility as drug delivery system for the cilastatin cargo kidney protector. While most nanotechnol. strategies focused on combating the different illnesses this methodol. emphasizes on reducing the kidney toxicity associated to cancer chemotherapy.

Keywords: cilastatin ; drug delivery systems ; drug-structure-directing agent (DSDA) ; mesoporous silica nanoparticles (MSNs) ; sustained and controlled release

Purchased from AmBeed:

Product Details of [ 82009-34-5 ]

CAS No. :82009-34-5 MDL No. :MFCD00867379
Formula : C16H26N2O5S Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 358.45 Pubchem ID :-
Synonyms :
MK0791
Chemical Name :(Z)-7-(((R)-2-Amino-2-carboxyethyl)thio)-2-((S)-2,2-dimethylcyclopropane-1-carboxamido)hept-2-enoic acid

Safety of [ 82009-34-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 82009-34-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 82009-34-5 ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Similar Product of
[ 82009-34-5 ]

Chemical Structure| 81129-83-1

A400757[ 81129-83-1 ]

Sodium (Z)-7-(((R)-2-amino-2-carboxyethyl)thio)-2-((S)-2,2-dimethylcyclopropane-1-carboxamido)hept-2-enoate

Reason: Free-salt

; ;